Izrael - héber - Ministry of Health

rafa laboratories ltd - fentanyl - מדבקות - fentanyl 25 mcg/hour - fentanyl - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fenta should only be used in patients who are already receiving opioid therapy who have demonstrated opioid tolerance.

Izrael - héber - Ministry of Health

rafa laboratories ltd - fentanyl - מדבקות - fentanyl 75 mcg/hour - fentanyl - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fenta should only be used in patients who are already receiving opioid therapy who have demonstrated opioid tolerance.

Izrael - héber - Ministry of Health

rafa laboratories ltd - fentanyl - מדבקות - fentanyl 100 mcg/hour - fentanyl - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fenta should only be used in patients who are already receiving opioid therapy who have demonstrated opioid tolerance.

Izrael - héber - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 100 mg; carbidopa 25 mg; entacapone 200 mg - levodopa - levodopa - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Izrael - héber - Ministry of Health

inovamed pharma ltd, israel - carbidopa; entacapone; levodopa - טבליות מצופות פילם - levodopa 50 mg; carbidopa 12.5 mg; entacapone 200 mg - levodopa and decarboxylase inhibitor - levodopa and decarboxylase inhibitor - treatment of patients with parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa/dopa decarboxylase (ddc) inhibitor treatment.

Izrael - héber - Ministry of Health

astrazeneca (israel) ltd - budesonide micronized; formoterol fumarate - אבקה לשאיפה - budesonide micronized 160 mcg/dose; formoterol fumarate 4.5 mcg/dose - formoterol and budesonide - formoterol and other drugs for obstructive airway diseases - asthma symbicort turbuhaler is indicated in the regular treatment of asthma in adults and adolescents age 12 years and above where use of a combination (inhaled corticosteroid and long acting beta-agonist) is appropriate: - patients not adequately controlled with inhaled corticosteroids and " as needed" inhaled short acting beta2- agonists. or - patients already adequately controlled on both inhaled corticosteroids and long acting beta2- agonists. copd symptomatic treatment of patients with severe copd (fev1 < 50 % predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular therapy with long-acting bronchodilators.

Izrael - héber - Ministry of Health

novartis israel ltd - omalizumab - אבקה וממס להכנת תמיסה להזרקה - omalizumab 150 mg/dose - omalizumab - omalizumab - xolair is indicated for adults and adolescents (12 years of age and above) with moderate to severe persistent asthma who have a positive skin test or in vitro reactivity to a perennial aeroallergen and whose symptoms are inadequately controlled with inhaled corticosteroids. xolair has been shown to decrease the incidence of asthma exacerbations in these patients. safety and efficacy have not been established in other allergic conditions.

Izrael - héber - Ministry of Health

novartis israel ltd - brinzolamide; timolol as maleate - תרחיף לעין - brinzolamide 10 mg/ml; timolol as maleate 5 mg/ml - timolol, combinations - timolol, combinations - decrease of intra-ocular pressure (iop) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient iop reduction.

Izrael - héber - Ministry of Health

novartis israel ltd - travoprost - תמיסה לעין - travoprost 0.004 %w/v - travoprost - travoprost - for the reduction of elevated intra ocular pressure in patients with open-angle glaucoma or ocular hypertension who are intolerant of other iop lowering medications or insufficiently responsive to another iop lowering medication.

Izrael - héber - Ministry of Health

novartis israel ltd - ranibizumab - תמיסה להזרקה - ranibizumab 10 mg/ml - ranibizumab - ranibizumab - treatment of patients with neovascular (wet) age-related macular degeneration (amd).treatment of adult patients with visual impairment due to diabetic macular oedema (dme) .the treatment of visual impairement due to macular oedema secondary to retinal vein occulsion (rvo).the treatment of visual impaiment due to choroidal neovacularization (cnv) secondary to pathologic myopia (pm).